BSH publish new guidelines on primary CNS diffuse large B-cell lymphoma
Published on: 17 December 2018New guidelines give a clear treatment pathway for people with primary CNS lymphoma
New guidelines published by the British Society of Haematology (BSH) provide healthcare professionals with evidence-based guidance on the diagnosis and management of people with diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS).
Around 1 in 100 cases of non-Hodgkin lymphomas are primary CNS lymphomas. The new BSH guidelines cover diagnosis and imaging, treatment recommendations (including for people whose lymphoma has not responded to treatment [refractory] or has come back [relapsed] after treatment and long-term follow-up. They emphasise the importance of a multidisciplinary team that includes neurologists as well as haematologists/oncologists.
Read more about DLBCL or primary CNS lymphoma or search for clinical trials suitable for people with primary CNS lymphoma.